Beta-defensins are multifunctional proteins that have an important role in the innate immune system. A cluster of beta-defensin genes shows common and extensive variation in copy number in humans. This copy number has been associated with differing susceptibility to Crohn’s disease and psoriasis. In this review, I summarise what is currently known about copy number variation (CNV) of beta-defensins, and discuss practical considerations when studying these genes, and copy number variation in general. I also suggest future directions for research, with an emphasis on improvement of methods for accurately typing CNV.

1.
Aitman TJ, Dong R, Vyse TJ, Norsworthy PJ, Johnson MD, et al: Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 439:851–855 (2006).
2.
Aldred PM, Hollox EJ, Armour JA: Copy number polymorphism and expression level variation of the human alpha-defensin genes DEFA1 and DEFA3. Hum Mol Genet 14:2045–2052 (2005).
3.
Armour JA, Sismani C, Patsalis PC, Cross, G: Measurement of locus copy number by hybridisation with amplifiable probes. Nucleic Acids Res 28:605–609 (2000).
4.
Armour JA, Rad IA, Hollox EJ, Akrami SM, Cross GS: Gene dosage analysis by multiplex amplifiable probe hybridization. Methods Mol Med 92:125–139 (2004).
5.
Armour JA, Palla R, Zeeuwen PL, Heijer MD, Schalkwijk J, Hollox EJ: Accurate, high-throughput typing of copy number variation using paralogue ratios from dispersed repeats. Nucleic Acids Res 35: e19 (2007).
6.
Awdeh ZL, Alper CA: Inherited structural polymorphism of the fourth component of human complement. Proc Natl Acad Sci USA 77:3576–3580 (1980).
7.
Barber JC, Joyce CA, Collinson MN, Nicholson JC, Willatt LR, et al: Duplication of 8p23.1: a cytogenetic anomaly with no established clinical significance. J Med Genet 35:491–496 (1998).
8.
Barber JCK, Maloney V, Hollox EJ, Stuke-Sontheimer A, du Bois G, et al: Duplications and copy number variants of 8p23.1 are cytogenetically indistinguishable but distinct at the molecular level. Eur J Hum Genet 13:1131–1136 (2005).
9.
Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, et al: Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 298:1025–1029 (2002).
10.
Candille SI, Kaelin CB, Cattanach BM, Yu B, Thompson DA, et al: A β-defensin mutation causes black coat color in domestic dogs. Science 318:1418–1423 (2007).
11.
Chung EK, Yang Y, Rupert KL, Jones KN, Rennebohm RM, et al: Determining the one, two, three, or four long and short loci of human complement C4 in a major histocompatibility complex haplotype encoding C4A or C4B proteins. Am J Hum Genet 71:810–822 (2002).
12.
Clayton DG, Walker NM, Smyth DJ, Pask R, Cooper JD, et al: Population structure, differential bias and genomic control in a large-scale, case-control association study. Nat Genet 37:1243–1246 (2005).
13.
Deutsch S, Choudhury U, Merla G, Howald C, Sylvan A, Antonarakis SE: Detection of aneuploidies by paralogous sequence quantification. J Med Genet 41:908–915 (2004).
14.
Fanciulli M, Norsworthy PJ, Petretto E, Dong R, Harper L, et al: FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet 39:721–723 (2007).
15.
Fellermann K, Stange DE, Schaeffeler E, Schmalzl H, Wehkamp J, et al: A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet 79:439–448 (2006).
16.
Fredman D, White SJ, Potter S, Eichler EE, Den Dunnen JT, Brookes AJ: Complex SNP-related sequence variation in segmental genome duplications. Nat Genet 36:861–866 (2004).
17.
Ganz T: Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 3:710–720 (2003).
18.
Giglio S, Broman KW, Matsumoto N, Calvari V, Gimelli G, et al: Olfactory receptor-gene clusters, genomic-inversion polymorphisms, and common chromosome rearrangements. Am J Hum Genet 68:874–883 (2001).
19.
Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM: Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88:553–560 (1997).
20.
Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, et al: The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307:1434–1440 (2005).
21.
Groth M, Szafranski K, Taudien S, Huse K, Mueller O, et al: High-resolution mapping of the 8p23.1 beta-defensin cluster reveals strictly concordant copy number variation of all genes. Hum Mutat 29:1247–1254 (2008).
22.
Harder J, Bartels J, Christophers E, Schroder JM: A peptide antibiotic from human skin. Nature 387:861 (1997).
23.
Harder J, Bartels J, Christophers E, Schroder JM: Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 276:5707–5713 (2001).
24.
Hazrati E, Galen B, Lu W, Wang W, Ouyang Y, et al: Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol 177:8658–8666 (2006).
25.
Hollox EJ, Armour JA: Directional and balancing selection in human beta-defensins. BMC Evol Biol 8:113 (2008).
26.
Hollox EJ, Armour JA, Barber JC: Extensive normal copy number variation of a beta-defensin antimicrobial-gene cluster. Am J Hum Genet 73:591–600 (2003).
27.
Hollox EJ, Davies J, Griesenbach U, Burgess J, Alton EW, Armour JA: Beta-defensin genomic copy number is not a modifier locus for cystic fibrosis. J Negat Results Biomed 4:9 (2005).
28.
Hollox EJ, Huffmeier U, Zeeuwen PL, Palla R, Lascorz J, et al: Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 40:23–25 (2008).
29.
Hoover DM, Rajashankar KR, Blumenthal R, Puri A, Oppenheim JJ, et al: The structure of human beta-defensin-2 shows evidence of higher order oligomerization. J Biol Chem 275:32911–32918 (2000).
30.
Howell MD, Streib JE, Leung DY: Antiviral activity of human beta-defensin 3 against vaccinia virus. J Allergy Clin Immunol 119:1022–1025 (2007).
31.
Joly S, Maze C, McCray PB Jr, Guthmiller JM: Human beta-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. J Clin Microbiol 42:1024–1029 (2004).
32.
Kisich KO, Heifets L, Higgins M, Diamond G: Antimycobacterial agent based on mRNA encoding human beta-defensin 2 enables primary macrophages to restrict growth of Mycobacterium tuberculosis. Infect Immun 69:2692–2699 (2001).
33.
Kisich KO, Howell MD, Boguniewicz M, Heizer HR, Watson NU, Leung DY: The constitutive capacity of human keratinocytes to kill Staphylococcus aureus is dependent on beta-defensin 3. J Invest Dermatol 127:2368–2380 (2007).
34.
Linzmeier RM, Ganz T: Human defensin gene copy number polymorphisms: comprehensive analysis of independent variation in alpha- and beta-defensin regions at 8p22-p23. Genomics 86:423–430 (2005).
35.
Locke DP, Sharp AJ, McCarroll SA, McGrath SD, Newman TL, et al: Linkage disequilibrium and heritability of copy-number polymorphisms within duplicated regions of the human genome. Am J Hum Genet 79:275–290 (2006).
36.
Maaser C, Kannengiesser K, Kucharzik T: Role of the melanocortin system in inflammation. Ann NY Acad Sci 1072:123–134 (2006).
37.
McCarroll SA, Altshuler DM: Copy-number variation and association studies of human disease. Nat Genet 39:S37–42 (2007).
38.
Oppenheim JJ, Yang D: Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 17:359–365 (2005).
39.
Quinones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, et al: Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 17:F39–48 (2003).
40.
Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, et al: Global variation in copy number in the human genome. Nature 444:444–454 (2006).
41.
Taudien S, Galgoczy P, Huse K, Reichwald K, Schilhabel M, et al: Polymorphic segmental duplications at 8p23.1 challenge the determination of individual defensin gene repertoires and the assembly of a contiguous human reference sequence. BMC Genomics 5:92 (2004).
42.
Tollner TL, Yudin AI, Tarantal AF, Treece CA, Overstreet JW, Cherr GN: Beta-defensin 126 on the surface of macaque sperm mediates attachment of sperm to oviductal epithelia. Biol Reprod 78:400–412 (2008).
43.
Torres AM, Wang X, Fletcher JI, Alewood D, Alewood PF, et al: Solution structure of a defensin-like peptide from platypus venom. Biochem J 341:785–794 (1999).
44.
Townson JR, Barcellos LF, Nibbs RJ: Gene copy number regulates the production of the human chemokine CCL3-L1. Eur J Immunol 32:3016–3026 (2002).
45.
Vylkova S, Nayyar N, Li W, Edgerton M: Human beta-defensins kill Candida albicans in an energy-dependent and salt-sensitive manner without causing membrane disruption. Antimicrob Agents Chemother 51:154–161 (2007).
46.
Weinberg A, Quinones-Mateu ME, Lederman MM: Role of human beta-defensins in HIV infection. Adv Dent Res 19:42–48 (2006).
47.
Whittington CM, Papenfuss AT, Bansal P, Torres AM, Wong ES, et al: Defensins and the convergent evolution of platypus and reptile venom genes. Genome Res 18:986–994 (2008).
48.
Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, et al: Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286:525–528 (1999).
49.
Yenugu S, Hamil KG, Radhakrishnan Y, French FS, Hall SH: The androgen-regulated epididymal sperm-binding protein, human beta-defensin 118 (DEFB118) (formerly ESC42), is an antimicrobial beta-defensin. Endocrinology 145:3165–3173 (2004).
50.
Yudin AI, Generao SE, Tollner TL, Treece CA, Overstreet JW, Cherr GN: Beta-defensin 126 on the cell surface protects sperm from immunorecognition and binding of anti-sperm antibodies. Biol Reprod 73:1243–1252 (2005).
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.